COMMUNIQUÉS West-GlobeNewswire

EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
12/09/2018
-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of [...]
Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD).
12/09/2018
Press release Malmö, September 12, 2018 Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD). Acarix AB (publ) ("Acarix") reports first sales in [...]
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
12/09/2018
SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced [...]
Solon Eiendom ASA – Primary insider notification
12/09/2018
(Oslo, Norway, September 11, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg has today through his wholly owned company Dukat AS bought 30.000 shares in Solon Eiendom ASA at a price of NOK 29. Following this [...]
Shire plc : Rule 2.9 Announcement
12/09/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 September 2018 [...]
Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress
12/09/2018
Late breaking oral presentation will provide additional detail around previously reported top-line results LONDON, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a [...]
Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease
12/09/2018
SHIRE GRANTED EU MARKETING AUTHORIZATION FOR VEYVONDI ® [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] FOR ADULTS WITH VON WILLEBRAND DISEASE Marketing Authorization will enable patient access to VEYVONDI ® [...]
Notice of Changes in the Supervisory Council of JSC Olainfarm
12/09/2018
The Joint Stock Company Olainfarm hereby informs about the receipt of the notice from the member of the Council of the Joint Stock Company "Olainfarm" Signe Baldere-Sildedze on leaving the Supervisory Council as of [...]
DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers
12/09/2018
Montrouge, France, September 12, 2018 DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers No safety concerns identified by independent DSMB Part B expected to [...]
DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide
12/09/2018
Montrouge, France, le 12 septembre (07h30 CEST), 2018 DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide Le DSMB [...]
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
12/09/2018
New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no injection site reactions[1] A [...]
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
12/09/2018
FDA to review supplemental Biologics License Application for Praluent ® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events FDA also recently approved Praluent label update for [...]
La FDA va examiner la demande supplémentaire de licence de produit biologique pour Praluent® (alirocumab), solution injectable, en tant que traitement potentiel dans la réduction d'événements cardi...
12/09/2018
La FDA va examiner la demande supplémentaire de licence de produit biologique pour Praluent ® (alirocumab), solution injectable, en tant que traitement potentiel dans la réduction d'événements cardiovasculaires majeurs [...]
INNATE PHARMA : first patient in the Phase I study of IPH5401 in combination with durvalumab
12/09/2018
Innate PHARMA announces enrollment of first patient in the phase i study of IPH5401 in combination with durvalumab (IMFINZI ® ) in solid tumors IPH5401 is a first-in-class antibody targeting the C5a receptor expressed [...]
INNATE PHARMA : premier patient dans l'étude de Phase I évaluant IPH5401 en combinaison avec durvalumab
12/09/2018
Innate Pharma annonce le recrutement du premier patient dans l'étude DE Phase I évaluant IPH5401 en combinaison avec durvalumab (Imfinzi ® ) dans différentes tumeurs solides IPH5401 est un anticorps « first-in-class » [...]
Biocartis Group NV: Disclosure of a transparency notification
12/09/2018
PRESS RELEASE: REGULATED INFORMATION 12 September 2018, 07:00 CEST Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, [...]
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
12/09/2018
MENLO PARK, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of [...]
Nuvectra® Announces Pricing of Follow-On Stock Offering
12/09/2018
PLANO, Texas, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the pricing of its underwritten follow-on public offering of 2,825,000 [...]
Endocyte Announces Pricing of Public Offering of Common Stock
12/09/2018
WEST LAFAYETTE, Ind., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the [...]

Pages